UNSPSC 51161562: Norethindrone and ethinyl estradiol combination

This classification denotes a mast cell stabilizer with the molecular structure C11H9NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1M887244YI chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-) but generally known as nivimedone, which bears US NIH Compound Identifier 64753. European Medicines Agency schedules Nivimedone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09333MIG.

The term NIVIMEDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17). SMILES: CC1=C(C=C2C(=C1)C(=O)C(C2=O)[N+](=O)[O-])C.

UNSPSC 51161562 Norethindrone and ethinyl estradiol combination is a Commodity code covering oral contraceptive products—specifically combination birth control pills—that state and local government health systems, correctional facilities, and public health agencies procure for distribution through pharmacy networks and health clinics. State and local buyers source these products as part of broader pharmaceutical supply agreements, typically through cooperative purchasing vehicles that bundle multiple generic and branded medications to achieve volume discounts and streamlined logistics. The issuing bodies acquiring under this code span state health departments, state departments of administration managing multi-jurisdictional cooperative purchasing, and subordinate state and local health facilities including county health systems and municipal clinics.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the primary recent opportunity—an RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026, due March 26, 2026—that bundles norethindrone and ethinyl estradiol combination products alongside other pharmaceutical lines for distribution across participating state and local facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Vendors must supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), maintain cGMP and Drug Supply Chain Security Act compliance, hold minimum insurance coverage including $5 million commercial general liability, and meet pricing structures weighted 75 percent on competitiveness with fixed or net-price options. Products must be market-available by May 15, 2026, with contract effectiveness July 1, 2026, and the cooperative agreement structure allows MMCAP to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.